WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

Novo Nordisk's high-dose Wegovy shows 20.7% weight loss in Phase 3 but falls short of Eli Lilly's Zepbound, raising questions ...

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...

FDA approves AstraZeneca's Calquence as first BTK inhibitor for first-line mantle cell lymphoma, leading BeiGene's Brukinsa ...

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...

FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...

Novartis is the latest drugmaker to sue the government for allegedly rejecting its proposed model to distribute federal drug ...

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

Teva is the latest drugmaker to file suit against Medicare negotiations. But unlike other companies that have challenged the ...

HHS told the Second Circuit that Boehringer Ingelheim’s voluntary participation in Medicare negotiations “undermines” its ...

After seeing its Covid-19 drug fail in a Phase 3 trial last year, Shionogi on Thursday won a $375 million award from HHS to ...

Novartis won a potentially short-lived victory in its fight across multiple courts to keep generic versions of its ...